Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP) has a beta value of 2.79 and has seen 2.96 million shares traded in the last trading session. The company, currently valued at $52.72M, closed the last trade at $0.21 per share which meant it lost -$0.01 on the day or -6.36% during that session. The ADAP stock price is -685.71% off its 52-week high price of $1.65 and -4.76% below the 52-week low of $0.22. If we look at the company’s 10-day average daily trading volume, we find that it stood at 3.55 million shares traded. The 3-month trading volume is 1.57 million shares.
The consensus among analysts is that Adaptimmune Therapeutics Plc ADR (ADAP) is Buy stock at the moment, with a recommendation rating of 2.14. 1 analysts rate the stock as a Sell, while 0 rate it as Overweight. 1 out of 6 have rated it as a Hold, with 4 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.17.
Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP) trade information
Sporting -6.36% in the red in last session, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the ADAP stock price touched $0.21 or saw a rise of 32.26%. Year-to-date, Adaptimmune Therapeutics Plc ADR shares have moved -61.76%, while the 5-day performance has seen it change -29.16%. Over the past 30 days, the shares of Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP) have changed -62.62%. Short interest in the company has seen 5.64 million shares shorted with days to cover at 4.59.
Wall Street analysts have a consensus price target for the stock at $3, which means that the shares’ value could jump 93.0% from current levels. The projected low price target is $1.0 while the price target rests at a high of $4.0. In that case, then, we find that the current price level is -1804.76% off the targeted high while a plunge would see the stock gain -376.19% from current levels.
Adaptimmune Therapeutics Plc ADR (ADAP) estimates and forecasts
The company’s shares have lost -77.59% over the past 6 months. Revenue growth from the last financial year stood is estimated to be -75.94%.
6 analysts offering their estimates for the company have set an average revenue estimate of 7.05M for the current quarter. 6 have an estimated revenue figure of 9.8M for the next ending quarter. Year-ago sales stood 5.68M and 128.23M respectively for this quarter and the next, and analysts expect sales will grow by 24.19% for the current quarter and -75.94% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 26.53% over the past 5 years.
ADAP Dividends
Adaptimmune Therapeutics Plc ADR is expected to release its next earnings report on 2025-Mar-23 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP)’s Major holders
Insiders own 0.31% of the company shares, while shares held by institutions stand at 49.59% with a share float percentage of 49.74%. Investors are also buoyed by the number of investors in a company, with Adaptimmune Therapeutics Plc ADR having a total of 94.0 institutions that hold shares in the company. The top two institutional holders are MATRIX CAPITAL MANAGEMENT COMPANY, LP with over 38.97 million shares worth more than $38.0 million. As of 2024-06-30, MATRIX CAPITAL MANAGEMENT COMPANY, LP held 2.5415% of shares outstanding.
The other major institutional holder is ECOR1 CAPITAL, LLC, with the holding of over 27.4 million shares as of 2024-06-30. The firm’s total holdings are worth over $26.72 million and represent 1.787% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are SPDR INDEX SHARES FUNDS-SPDR(R) Portfolio Developed World ex-US ETF and SEI INSTITUTIONAL INTERNATIONAL TRUST-SIT INTERNATIONAL EQUITY FUND . As of Feb 28, 2025 , the former fund manager holds about 0.11% shares in the company for having 272.49 shares of worth $56133.0 while later fund manager owns 246.74 shares of worth $50829.0 as of Feb 28, 2025 , which makes it owner of about 0.10% of company’s outstanding stock.
